
About iSpecimen
iSpecimen is a publicly listed company based in Lexington (United States) founded in 2009. It operates as a provider of a biorepository of human clinical specimens. iSpecimen has raised $11.86 million across 9 funding rounds. The company has 24 employees. iSpecimen offers products and services including iSpecimen Marketplace, Biofluids Inventory, and Tissue Samples. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Biorepository. Its competitors include GenVault Corporation, PrecisionMed, Cryoniss, AminoChain and ViaCell and 2 more; 5 of its 7 listed competitors have raised funding.
Company details
iSpecimen was founded in 2009 and is based in Lexington, United States. Human clinical specimens are provided by the company to therapeutic, diagnostic, and academic research sectors through an online platform. Liquid and solid samples, such as plasma, serum, whole blood, urine, cerebrospinal fluid, and FFPE blocks or slides, are made available. Contract research organizations, government agencies, and academic institutions are included among the customers served.
- Headquarters Lexington, United States
- Employees 24
- Stage Public
- SectorsHealthcare
- Website ispecimen.com
- Social LinkedIn X Facebook YouTube
- Annual Revenue$1.93 M (USD)-79.24as on Dec 31, 2025
- Net Profit-$10.49 M (USD)16.09as on Dec 31, 2025
- EBITDA-$5.38 M (USD)46.81as on Dec 31, 2025
- Total Equity Funding$11.86M (USD)
in 9 rounds
- Latest Funding Round$2.5M (USD), Post-IPO
May 2026
- Employee Count24
Products & Services of iSpecimen
iSpecimen offers a comprehensive portfolio of products and services, including iSpecimen Marketplace, Biofluids Inventory, and Tissue Samples.
Online system for accessing and ordering human biospecimens for research.
Collection of biofluids like blood and urine for life science studies.
Provision of fresh, frozen, and processed tissues for medical research.
Apps and channels of iSpecimen
its YouTube channel iSpecimen Inc. has 42 subscribers.
Funding Insights of iSpecimen
iSpecimen has successfully raised a total of $11.86M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $2.5 million completed in May 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $11.86M
- Total Rounds 9
- Last Round Post-IPO β $2.5M
- First Round $2M
(Jul 2012)
All 9 funding rounds of iSpecimen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2026 | $2.5M | Post-IPO | β | β | β |
| Dec 2025 | $5.5M | Post-IPO | β | β | β |
| Aug 2025 | $1.75M | Post-IPO | β | β | β |
| Aug 2025 | $1.75M | Post-IPO | β | β | β |
| Nov 2021 | $21M | Post-IPO | β | β | β |
| Aug 2018 | $800,000 | Series B | β | β | β |
| Mar 2017 | $500,000 | Series B | β | β | β |
| Sep 2014 | $8.56M | Series B | β | β | β |
| Jul 2012 | $2M | Seed | β | β | β |
People of iSpecimen
11 people are tracked at iSpecimen (1 in leadership, 10 in board & advisors); the tracked headcount is 24.
| Name | Role | Group |
|---|---|---|
David Wages | Chief Medical Officer | Leadership |
Andrew Ross | Board Member | Board & advisors |
George Scholl | Board Member | Board & advisors |
John L. Brooks III | Director | Board & advisors |
Steven Gullans | Board Member | Board & advisors |
Bill O'Donnell | Advisor | Board & advisors |
Ed Trautman | Advisor | Board & advisors |
Robert Babkowski | Advisor | Board & advisors |
Martin Ferguson | Advisor | Board & advisors |
Jim Vaught | Advisor | Board & advisors |
Joseph J. Basile | Board Member | Board & advisors |
Complete people profiles for iSpecimen
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of iSpecimen
iSpecimen is a publicly listed company on the NASDAQ with ticker symbol ISPC in USA, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Jun 2021
- Listed onNASDAQ: ISPC
- Listed entityiSpecimen Inc.
- Exchange sectorCommercial services
Timeline of iSpecimen
4 dated milestones of iSpecimen across 17 years, from founding to its latest funding, stage changes and deals.
- Founded iSpecimen is founded.
- Funding First funding round of $2.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $2.5M.
Competitors of iSpecimen
iSpecimen has 7 listed competitors in our database, 5 of them funded. They include GenVault Corporation, PrecisionMed, Cryoniss, AminoChain and ViaCell, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| genvault.com | 2000 | Carlsbad, United States | $47.8M | – | Biosamples are stabilized, transported, stored, and retrieved by GenVault. | |
| precisionmed.com | 1996 | San Diego, United States | – | – | Human biological materials for research are supplied via a biorepository. | |
| cryoniss.com | 2018 | Macclesfield, United Kingdom | $683,055 | 9 | Provider of biobanking services for life sciences industries | |
| aminochain.io | 2022 | New York, United States | $7.07M | – | A blockchain-based platform for tokenizing and incentivizing stem cell donations | |
| viacellinc.com | 1994 | Cambridge, United States | $63M | – | Provider of services for collecting and preserving umbilical cord blood stem cells | |
| indivumed.com | 2002 | Hamburg, Germany | – | 178 | Biospecimens are collected, preserved, and analyzed for oncology services. | |
| biostorage.com | 2002 | Indianapolis, United States | $8.77M | – | Provides bio repository services |
Detailed competitors of iSpecimen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of iSpecimen
The website of iSpecimen (ispecimen.com) receives about 5.4K visits a month.
- Monthly visits5.4K
▼ 14.3% vs previous month
Websites whose visitors overlap most with iSpecimen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
katefarmsmedical.com | katefarmsmedical.com | 100% | – | #1,279,260 | β |
| accellent.com | 94% | – | – | View details | |
medicalbiostatistics.com | medicalbiostatistics.com | 94% | – | – | β |
kenvuepro.com | kenvuepro.com | 65% | – | #304,388 | β |
| precisionformedicine.com | 64% | 36.8K | #1,000,701 | View details | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 10 similar websites and full traffic analytics for iSpecimen
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 10 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
10 companies that operate in the same segment as iSpecimen (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | 1,111 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ispecimen
Complete news archive for iSpecimen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about iSpecimen
iSpecimen was founded in 2009 and raised its 1st funding round 3 years after it was founded.
iSpecimen is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
iSpecimen is a funded company, having raised a total of $11.86M across 9 funding rounds to date. The company's 1st funding round was a Seed of $2M, raised on Jul 2012.
iSpecimen has 24 employees.
Annual revenue of iSpecimen is $1.93M as on Dec 31, 2025.
iSpecimen was founded in 2009 and is based in Lexington, United States. Human clinical specimens are provided by the company to therapeutic, diagnostic, and academic research sectors through an online platform. Liquid and solid samples, such as plasma, serum, whole blood, urine, cerebrospinal fluid, and FFPE blocks or slides, are made available. Contract research organizations, government agencies, and academic institutions are included among the customers served.
iSpecimen's top competitors include AminoChain, GenVault Corporation and Cryoniss.
iSpecimen offers iSpecimen Marketplace, Biofluids Inventory, and Tissue Samples.
Yes, iSpecimen is publicly traded on NASDAQ under the ticker symbol ISPC.
